These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 37900995)

  • 1. Prostaglandin F
    Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ
    World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IFI6 Downregulation Reverses Oxaliplatin Resistance of Colorectal Cancer Cells by Activating the ROS-Induced p38MAPK Signaling Pathway.
    Huang C; Zhou T; Ma L; Zhao S
    Biol Pharm Bull; 2023; 46(1):26-34. PubMed ID: 36596524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
    Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
    Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.
    Gao R; Fang C; Xu J; Tan H; Li P; Ma L
    Arch Biochem Biophys; 2019 Mar; 663():183-191. PubMed ID: 30639170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species-mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin-resistant colorectal cancer cells.
    Zhang Z; Shen C; Zhou F; Zhang Y
    Drug Dev Res; 2023 May; 84(3):542-555. PubMed ID: 36779379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
    Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
    Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions.
    Zhang J; Li C; Sun L; Sun D; Zhao T
    Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37921068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
    Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
    Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydrotanshinone I Inhibits the Proliferation and Growth of Oxaliplatin-Resistant Human HCT116 Colorectal Cancer Cells.
    Wang M; Xiang Y; Wang R; Zhang L; Zhang H; Chen H; Luan X; Chen L
    Molecules; 2022 Nov; 27(22):. PubMed ID: 36431875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of resistance to oxaliplatin by vorinostat in human colorectal cancer cells through inhibition of Nrf2 nuclear translocation.
    Tanaka S; Hosokawa M; Tatsumi A; Asaumi S; Imai R; Ogawara KI
    Biochem Biophys Res Commun; 2022 Jun; 607():9-14. PubMed ID: 35358872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-κB-Nrf2 signaling in colorectal cancer cell.
    Wang Z; Sun X; Feng Y; Wang Y; Zhang L; Wang Y; Fang Z; Azami NLB; Sun M; Li Q
    Phytomedicine; 2021 Feb; 82():153414. PubMed ID: 33461143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Cyanidin-3-
    Kurter H; Basbinar Y; Ellidokuz H; Calibasi-Kocal G
    Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kruppel-like factor 5 enhances proliferation, lipid droplet formation and oxaliplatin resistance in colorectal cancer by promoting fatty acid binding protein 6 transcription.
    Zuo Q; Xu Q; Li Z; Luo D; Peng H; Duan Z
    Anticancer Drugs; 2023 Nov; 34(10):1171-1182. PubMed ID: 37067981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IRF-1 mediated long non-coding RNA PVT1-214 promotes oxaliplatin resistance of colorectal cancer via miR-128 inhibition.
    Tong D; Zou E; Bai L; Ma J; Guo N; Wang H; Jiang L
    J BUON; 2020; 25(5):2205-2214. PubMed ID: 33277837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-hydroxybutyrate resensitizes colorectal cancer cells to oxaliplatin by suppressing H3K79 methylation in vitro and in vivo.
    Deng M; Yan P; Gong H; Li G; Wang J
    Mol Med; 2024 Jun; 30(1):95. PubMed ID: 38910244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
    Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
    J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of orexin A on PTGS2, PTGES, CBR1 and PGFS mRNA transcript abundances and prostaglandin E
    Orzechowska K; Kiezun M; Rytelewska E; Gudelska M; Kisielewska K; Kopij G; Dobrzyn K; Zaobidna E; Szymanska K; Kaminski T; Smolinska N
    Anim Reprod Sci; 2022 Feb; 237():106910. PubMed ID: 34974394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis.
    Li L; Shang J; Zhang Y; Liu S; Peng Y; Zhou Z; Pan H; Wang X; Chen L; Zhao Q
    Oncol Rep; 2017 Sep; 38(3):1383-1392. PubMed ID: 28731151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gegen Qinlian Decoction reverses oxaliplatin resistance in colorectal cancer by inhibiting YTHDF1-regulated m6A modification of GLS1.
    Lin X; Xu L; Gu M; Shao H; Yao L; Huang X
    Phytomedicine; 2024 Oct; 133():155906. PubMed ID: 39089089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of key lncRNAs associated with oxaliplatin resistance in colorectal cancer cells and isolated exosomes: From In-Silico prediction to In-Vitro validation.
    Sahebnasagh R; Deli H; Shadboorestan A; Vakili-Ghartavol Z; Salehi N; Komeili-Movahhed T; Azizi Z; Ghahremani MH
    PLoS One; 2024; 19(10):e0311680. PubMed ID: 39401197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.